Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 300 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 150 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

opella healthcare france s.a.s. - triamcinolonum acetóníð - nefúði, dreifa - 55 míkróg/skammt

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - deferoxaminum mesýlat - stungulyfs-/innrennslisstofn, lausn - 500 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

opella healthcare france s.a.s. - natrii picosulfas inn - dropar til inntöku, lausn - 7,5 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - dexamethasonum fosfat - augndropar, dreifa - 1 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - neomycinum súlfat; polymyxinum b súlfat; dexamethasonum fosfat - augndropar, dreifa

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ge healthcare as - flútemetamól (18f) - radionuclide imaging; alzheimer disease - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. vizamyl er radiopharmaceutical lyf fram í sneiðmyndatöku losun höfði (gÆludÝr) hugsanlegur beta amyloid neuritic sýklum þéttleika í heila fullorðinn sjúklinga með vitsmunalegum skert sem eru metin fyrir alzheimer (ad) og aðrar ástæður vitsmunalegum skert. vizamyl skal nota í tengslum við klínískt mat. neikvæð skanna sýnir dreifður eða enginn skellum, sem er ekki í samræmi við greiningu á ad.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

eurocept international bv - carglumic acid - hyperammonemia; amino acid metabolism, inborn errors - Önnur meltingarvegi og efnaskipti vörur, - ucedane is indicated in treatment of:hyperammonaemia due to n-acetylglutamate synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - Æxlishemjandi lyf - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. sjúklingar sem hafa lítil eða mjög lítil hætta á endurkomu ætti ekki að fá viðbótar meðferð. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. nema í nýlega greind langvarandi áfanga cml, það eru ekki stjórnað rannsóknir sýna klínískum gagnast eða jókst að lifa fyrir þessum sjúkdómum.